Baricitinib therapy in critical COVID-19: plenty of promise, but no hard evidence yet

Crit Care. 2024 Dec 18;28(1):409. doi: 10.1186/s13054-024-05191-9.

Seung-Hun You¹, Moon Seong Baek², Tae Wan Kim², Sun-Young Jung^{3

4}, Won-Young Kim⁵

¹ Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Chung-Ang University, Seoul, Republic of Korea.
² Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
³ Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Chung-Ang University, Seoul, Republic of Korea. jsyoung@cau.ac.kr.
⁴ College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea. jsyoung@cau.ac.kr.
⁵ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea. wykim81@cau.ac.kr.

No abstract available

Publication types